Gamelin Erick (CIK 0001950551)

Latest company ownership

ACRV - Acrivon Therapeutics, Inc.
Role: Chief Development Officer
Shares held
15,283
Last filed at
Nov 18, 2025
Confidence Score
47.5
2025Q4
Confidence Score History
2023Q4 2025Q4

Recent buy/sell transactions

Exec date Filing date Company Role Signal Confidence Shares % of shares Under plan? Amount (USD)
Nov 14, 2025 Nov 18, 2025 Acrivon Therapeutics, Inc. Chief Development Officer Sell 47.5 -403 -2.57% ✗ $902.7
Aug 14, 2025 Aug 18, 2025 Acrivon Therapeutics, Inc. Chief Development Officer Sell 47.5 -403 -2.50% ✗ $560.2
May 14, 2025 May 16, 2025 Acrivon Therapeutics, Inc. Chief Development Officer Sell 47.5 -403 -2.44% ✗ $459.4
Feb 14, 2025 Feb 19, 2025 Acrivon Therapeutics, Inc. Chief Development Officer Sell 47.5 -469 -2.77% ✗ $2.5K
Nov 14, 2024 Nov 18, 2024 Acrivon Therapeutics, Inc. Chief Development Officer Sell 47.5 -402 -2.32% ✗ $3.2K
Aug 14, 2024 Aug 16, 2024 Acrivon Therapeutics, Inc. Chief Development Officer Sell 47.5 -402 -2.26% ✗ $2.8K
May 14, 2024 May 16, 2024 Acrivon Therapeutics, Inc. Chief Development Officer Sell 47.5 -402 -2.21% ✗ $3.4K
Feb 14, 2024 Feb 16, 2024 Acrivon Therapeutics, Inc. Chief Development Officer Sell 47.5 -468 -2.51% ✗ $1.6K
Nov 14, 2023 Nov 16, 2023 Acrivon Therapeutics, Inc. Chief Medical Officer Sell 47.5 -1,395 -6.96% ✗ $7.1K